Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

Summary

Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States. Patients with severe AD will be studied during a 24-week study with systemic cyclosporine (Neoral, capsule form) to evaluate the immune suppression and pathological correlation of cyclosporine A in these patients in order to determine the extent to which immune activation drives the pathological epidermal phenotype.

Timeline

Start

2010-06

Primary completion

2014-12

Completion

2014-12

Drugs

Indications